EFFECT OF PEGYLATED TRANSFERSOMES CONTAINING MACROMOLECULAR PROTEIN ON TRANSDERMAL DELIVERY

Main Article Content

Kritsanaporn Tansathien
Puvamin Suriyaaumporn
Tanasait Ngawhirunpat
Worranan Rangsimawong
Praneet Opanasopit

Abstract

Hydrophilic protein macromolecules are limited to passively penetrate through the skin. The objective of this study was to investigate the effect of various concentrations of PEGylation (1, 5 and 10%) grafted liposomes for delivering macromolecular protein through the skin. PEGylated transfersomes composed of phosphatidylcholine (PC), cholesterol (Chol), DSPE-PEG2000, Tween20 and d-limonene were prepared for loading bovine serum albumin (BSA) as macromolecular protein model. The characterizations of these nanocarriers were evaluated such as size, PDI, zeta potential and %loading capability (%LC). The in vitro permeation study was performed by using Franz diffusion cells through porcine skins.  BSA-FITC content was analyzed using a fluorescence spectrophotometer. For the results, all formulations showed narrow size distributions (PDI<0.3). The sizes and zeta potential of all transfersomes were 43.90±1.75, 44.39±7.20 and 42.98±0.32 nm, and -9.95±0.22, -12.53±1.96, -12.93±1.44 mV, respectively, which increasing the PEGylation decreased the particle size and increased negative charge. %LC of all transfersomes was in the range of 9.70-13.33. The permeation study showed that the skin treated with 5% transfersomes has higher macromolecular protein delivery through skin than other formulations, because higher hydrophilic PEG content might provide higher conformational change on the surface of the transfersomes, leading to increase the skin hydration and then enhance the hydrophilic BSA-FITC penetrated through the skin. In conclusion, the concentration of PEGylation on the liposomes structure significantly affects the physicochemical properties (p < 0.05) leading to improve the skin permeability of hydrophilic protein macromolecules.

Article Details

How to Cite
1.
Tansathien K, Suriyaaumporn P, Ngawhirunpat T, Rangsimawong W, Opanasopit P. EFFECT OF PEGYLATED TRANSFERSOMES CONTAINING MACROMOLECULAR PROTEIN ON TRANSDERMAL DELIVERY. Interprof J Health Sci [Internet]. 2019 Dec. 25 [cited 2024 Dec. 22];17(2):48-54. Available from: https://li05.tci-thaijo.org/index.php/IJHS/article/view/20
Section
Research Articles

References

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. 2013. Liposome: classification, preparation, and applications. Nanoscale Research Letters. 8(1): 102.

Alfredson T, Zeller M. 2012. Formulation technologies to overcome poor drug-like properties. Drug Discovery Today: Technologies. 9(2): e71-e72.

Ashtikar M, Nagarsekar K, Fahr A. 2016. Transdermal delivery from liposomal formulations – Evolution of the technology over the last three decades. Journal of Controlled Release. 242: 126-140.

Bulbake U, Doppalapudi S, Kommineni N, Khan W. 2017. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 9(2): 12.

Chen J, Lu W-L, Gu W, Lu S-S, Chen Z-P, Cai B-C. 2013. Skin permeation behavior of elastic liposomes: role of formulation ingredients. Expert Opinion on Drug Delivery. 10(6): 845-856.

Dragicevic N, Maibach H. 2018. Combined use of nanocarriers and physical methods for percutaneous penetration enhancement. Advanced drug delivery reviews. 127: 58-84.

Garbuzenko O, Barenholz Y, Priev A. 2005. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chemistry and Physics of Lipids. 135(2): 117-129.

Godin B, Touitou E. 2007. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Advanced Drug Delivery Reviews. 59(11): 1152-1161.

Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine. 1(3): 297-315.

Melis Ç, Seyda B, Ali DS. 2014. Liposomes as Potential Drug Carrier Systems for Drug Delivery. Application of Nanotechnology in Drug Delivery. pp. 1-50.

Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, et al. 1991. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proceedings of the National Academy of Sciences of the United States of America. 88(24): 11460-11464.

Rangsimawong W, Opanasopit P, Rojanarata T, Ngawhirunpat T. 2014. Terpene-Containing PEGylated Liposomes as Transdermal Carriers of a Hydrophilic Compound. Biological and Pharmaceutical Bulletin. 37(12): 1936-1943.

Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. 2015. Advances and Challenges of Liposome Assisted Drug Delivery. Frontiers in Pharmacology. 6(286).

Yan X, Scherphof GL, Kamps JAAM. 2005. Liposome Opsonization. Journal of Liposome Research. 15(1 2):109-139.

Zylberberg C, Matosevic S. 2016. Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape. Drug Delivery. 23(9): 3319-3329.